Corcept's ROSELLA Phase 3 posts results for relacorilant plus nab-paclitaxel in ovarian cancerSep 25Trial updateCorcept Therapeuticspaclitaxel
Corcept names Justin Gunn to succeed retiring endocrinology president Sean MaduckSep 23PeopleCorcept Therapeutics
FDA tells Compass Therapeutics to run survival trial before BLA for tovecimigSep 22Clinical readoutCompass Therapeutics
Teva gets labeling supplement approved for injectable PaclitaxelSep 11Regulatory decisionpaclitaxelTeva Pharmaceutical Industries Ltd
Revolution Medicines registers Phase 3 RASolute 309 in KRAS G12D pancreatic cancerSep 8Trial updatedaraxonrasibRevolution Medicines, Inc.
AbbVie posts results from terminated emraclidine trial, opens two studies to recruitmentAug 21Weekly roundup, 4 itemsAbbVieemraclidine
Can-Fite reports preclinical data on namodenoson-gemcitabine combination in pancreatic cancerAug 17Clinical readoutCan-Fite BioPharmagemcitabine
RenovoRx completes Phase III enrollment, raises 2026 revenue guidanceAug 13Quarterly updateRenovoRx, Inc
Eikon Therapeutics reports Q2 2026 results with seven ESMO abstracts and melanoma trial progressAug 13Quarterly updateEikon Therapeutics
Theriva doses first patients in VIRAGE2 trial of VCN-01 in pancreatic cancerAug 11Quarterly updateTheriva Biologics, Inc.
MD Anderson registers Phase II trial of Summit's ivonescimab in rare appendix cancerAug 10Trial updateivonescimabSummit Therapeutics
Theriva doses first patient in VIRAGE2 trial testing repeat VCN-01 dosing in pancreatic cancerAug 6Clinical readoutTheriva Biologics, Inc.
Puma Biotechnology raises 2026 guidance on NERLYNX demand, details alisertib trial timelineAug 6Quarterly updatealisertibneratinib
Compass Therapeutics awaits FDA input on tovecimig biliary cancer dataAug 6Quarterly updateCompass Therapeutics
ROCKIF trial of defactinib in ovarian cancer terminated for lost funding; results postedJul 31Trial updatedefactinibVerastem, Inc.
Corcept raises 2026 revenue guidance to $1.1-$1.2 billion after Lifyorli launch quarterJul 29Quarterly updateCorcept Therapeuticsmifepristone
Theriva gets Spanish authorization for VIRAGE2 trial of VCN-01 in pancreatic cancerJul 7Clinical readoutTheriva Biologics, Inc.
BMS posts PRIME-HCC results; adds SOTYKTU label update, Phase 3 lung trialJul 2Weekly roundup, 7 itemsBristol Myers Squibbcisplatin
Sanofi posts pediatric Hectorol results; USC germ cell trial data also reportedJul 2Weekly roundup, 4 itemsdoxercalciferolSanofi
Sign inSign in